Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

17α-Hydroxyprogesterone Caproate for the Prevention of Adverse Neonatal Outcome in Multiple Pregnancies: A Randomized Controlled Trial

O'Brien, John M. MD

doi: 10.1097/AOG.0b013e318244b0ef
Departments: Letters to the Editor

University of Kentucky, Department of Maternal-Fetal Medicine, Lexington, Kentucky

Financial Disclosure: Dr. O'Brien was involved in studies of progesterone gel treatment for preterm birth prevention sponsored by a maker of progesterone gel. He serves on advisory boards and acts as as a consultant for Watson Pharmaceuticals, a company with a financial interest in marketing vaginal progesterone gel for preterm birth prevention, and he is listed in the patent on the use of all progesterone compounds to prevent preterm birth (U.S. Patent Number 7,884,093: Progesterone for the Treatment and Prevention of Spontaneous Preterm Birth).

© 2012 by The American College of Obstetricians and Gynecologists.